Vascular Access Devices Market Size & Share 2025 – 2034

Vascular Access Devices Market Size

The global vascular access devices market size was valued at USD 5.8 billion in 2024 and is projected to exhibit 7.1% CAGR from 2025-2034. The growing prevalence of chronic diseases, including cancer, kidney failure, and cardiovascular diseases, worldwide drives the demand for vascular access devices. The World Health Organization (WHO) indicated 20 million estimated new cases of cancer and 9.7 million deaths in 2022. They need prolonged intravenous treatments in oncology like chemotherapy, dialysis, and administration of antibiotics, necessitating trustworthy vascular access.

Also supporting this demand is the aging population, whereby elderly patients tend to need more frequent medical treatment because of these health conditions. According to the United Nations, by 2050 a sixth of the world's population will be above the age of 65 years, which reflects ongoing demand for vascular access devices in the management of chronic diseases.
 

Additionally, the increase in elective and emergency surgeries and rising hospitalizations across the globe drive persistent demand for vascular access devices. An estimated 234 million major surgeries are conducted globally annually, as estimated by the WHO. Fluid management, administration of anesthesia, and post-surgical care all rely on vascular access devices. Healthcare infrastructure expansion, especially in emerging markets, underpins continued vascular access device growth in the inpatient setting.
 

Vascular access devices are the devices that facilitate direct access to a patient's vascular system to administer or remove fluids, blood products, medicines, or nutrients. These devices play a significant role in a clinical environment to support a variety of procedures ranging from short procedures like fluid replacement and anesthesia in surgery to longer therapy like chemotherapy, dialysis, and intravenous nutrition.
 

Vascular Access Devices Market Trends

• Medical practitioners are adopting minimally invasive, image-guided techniques of conducting vascular access placements, particularly under ultrasound guidance. This approach reduces complications related to insertion, improves patient comfort, and improves procedural success rates. The trend has generated increased demand for vascular access devices with enhanced visualization and safety features.
   
• In addition to this, companies are designing vascular access devices with antimicrobial coating and resistance to materials against thrombosis for the prevention of catheter-associated bloodstream infection (CRBSI) and thrombosis. For instance, Becton Dickinson and Company provides the PowerGlide Pro Midline Catheter and BioFlo PICC with Endexo and BD Vascular Access Shield Technology, which uses thrombus and infection resistant materials. Also, Teleflex makes the ARROWg+ard Blue catheter which contains a chlorhexidine coating that proved to decrease bacterial adhesion.
   
• These catheters are being utilized across oncology care settings and critical care environments, where long-term access and infection control are primarily considered during purchasing decisions.
   
• Also, owing to increasing focus on value-based care, home-based treatment processes is driving the market. PICCs and implantable ports are some of the devices that allow patients to undergo intravenous therapy in the outpatient or home setting, reducing hospitalization. The trend is particularly observed in treating chronic illness, such as cancer and infection.
   
• Vascular access devices are increasingly incorporating digital sensors and connectivity for real-time monitoring of flow, pressure, and device status. These technologies improve timely detection of occlusion or device failure and reduce complications. The trend is part of the broader convergence of digital health and remote patient management.
   

Vascular Access Devices Market Analysis

Based on product, the market is bifurcated into peripheral vascular access devices and central vascular access devices. The central vascular access devices segment dominated the market with the largest revenue share of 63.9% in 2024.
 

• Central vascular access devices play a very significant role in the administration of repeated or continuous infusions, especially in cancer therapy.
   
• The world-wide growth in cancer patients and chemotherapy as a common form of treatment is generating a high demand for tunneled catheters, implantable ports, and PICCs. These pose fewer insertion frequencies and lower patient discomfort for long periods of treatment.
   
• Product innovations such as antimicrobial coatings, anti-thrombogenic materials, and closed-system connectors have improved CVAD safety profiles. These innovations minimize complications such as infections, catheter-related bloodstream infections (CRBSIs), and clotting, leading to higher adoption by healthcare providers.
   
• Further, newer insertion techniques, like image-guided placements, have enhanced the efficiency and safety of CVAD utilization in different health facilities, driving their adoption.
   

Based on application, the vascular access devices market is segmented into drug administration, fluid and nutrition administration, blood transfusion, diagnostic testing, and other applications. The drug administration segment dominated the market with the largest revenue of USD 2.4 billion in 2024.
 

• The rising incidence of chronic illnesses, such as cancer, infectious diseases, autoimmune diseases, and cardiovascular disease, is propelling the use of vascular access devices in long-term drug therapy. Chronic illnesses contribute to 32% of total deaths worldwide, with cardiovascular disease accounting for 17.9 million deaths each year, according to the Heart Research Institute.
   
• Continuous or chronic drug infusion for antibiotics, chemotherapy drugs, immunotherapies, and biologics, are frequently administered during treatments for such diseases. As a result, increased disease burden dictates the need for reliable vascular access solutions that aid in long-term drug delivery.
   
• In addition, the worldwide healthcare systems are facilitating a shift toward home care and outpatient care rather than inpatient care in the interest of cost reduction as well as in increasing patient comfort. This change is propelling the use of vascular access devices for drug administration outside hospitals, particularly in those patients requiring prolonged antibiotic therapy, pain management, or parenteral nutrition, aiding to the revenue growth in the segment.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on end use, the vascular access devices market is segmented into hospitals and clinics, ambulatory surgical centers, homecare settings, and other end users. The hospitals and clinics segment dominated the market with a share of 56.2% in 2024.
 

• The increase in elective and advanced surgical procedures worldwide across specialty clinics and hospitals creates ongoing demand for vascular access products. They are utilized during intraoperative anesthesia, fluid management, and post-operative medication administration. Medical facilities such as hospitals and clinics require both short-term products such as peripheral IVs and midlines and longer-term ones for extended recovery periods.
   
• Hospitals and clinics are facing increasing clinical and regulatory pressures to reduce catheter-related bloodstream infections (CRBSIs) and other complications. This has encouraged increased adoption of sophisticated antimicrobial-coated vascular access devices with closed systems and securement.
   
• Further, demand across acute healthcare settings such as hospitals, for reducing healthcare associated infection and protecting patients is redirecting market demand towards using safer and advanced vascular access products with antimicrobial coating, which is further aiding to the revenue growth in the segment.
   

The North America vascular access devices market was valued at USD 2.6 billion in 2024 and is expected to grow at a CAGR of 7% over the forecast period. The market is driven by the increasing incidence of chronic conditions, cancer, and cardiovascular diseases across the region.
 

The U.S. market is projected to grow significantly from USD 2.3 billion in 2024 to USD 4.6 billion by 2034.
 

• In the U.S., the expanding epidemic of chronic diseases, such as diabetes, cancer, cardiovascular disease, and renal failure, has fueled the need for long-term intravenous treatments. Six out of ten U.S. adults have at least one chronic disease, and four out of ten have two or more, reports the Centers for Disease Control and Prevention. Vascular access devices are the mainstay for the delivery of chemotherapy, dialysis, parenteral nutrition, and prolonged antibiotic regimens.
   
• The integration of these chronic illnesses and the aging population, with the U.S. Census Bureau estimating 77 million individuals aged 65 and older in 2034, continues to escalate the demand for central and peripheral access devices within hospital and home care settings. This demographic change reflects a pattern of consistent growth in the use of vascular access devices in the management of chronic disease.
   
• The U.S. healthcare system is shifting towards home and outpatient care, supported by increasing hospitalization costs and patient preferences for home treatment. Vascular access devices, especially PICCs and implantable ports, allow for the safe, long-term administration of drugs outside of hospitals.
• The growth in ambulatory infusion centers and home infusion services nationwide is driving tremendous growth in the market.
   

Europe vascular access devices market was valued at USD 1.5 billion in 2024 and is expected to grow at a CAGR of 6.8% over the forecast period.
 

• The population in Europe is aging rapidly, particularly in countries such as Italy and Germany, and accompanying this is a rising incidence of long-term diseases like kidney disease, cancer, and cardiovascular disease.
   
• These are typically long-term diseases that require prolonged intravenous therapy, dialysis, or prolonged hospitalizations, thus permanent need for vascular access devices to facilitate treatment administration.
   
• Additionally, universal coverage by publicly funded programs exists in most countries of Europe, making the application of sophisticated medical technology such as vascular access devices possible.
   
• National health policy encourages reimbursement programs and evidence-based, cost-reducing device use, which promotes inpatient and outpatient utilization. Hence, the aforementioned factors are expected to significantly boost regional growth over the forecast period.
   

The vascular access devices market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The UK's increasing incidence of cancer leads to the need for central vascular access devices in chemotherapy, such as implantable ports and tunnelled catheters. According to Cancer Research UK, over 500,000 individuals in the UK will be diagnosed with cancer annually by 2040. NHS pathways for cancer treatment depend on long-term vascular access for drug administration.
   
• Oncology services and cancer screening program expansion indicate long-term growth in the use of vascular access devices. The commitment of the NHS Cancer Programme to early diagnosis and more convenient access to treatment suggests long-term growth in vascular access device demand for the provision of cancer care.
   
• The UK National Health Service (NHS) is under increasing pressure to reduce the expense of healthcare and hospital bed occupancy. This has encouraged increased use of vascular access devices, in the form of PICCs and midlines, that enable discharge early and home treatment.
   
• These devices allow treatment to be delivered with intravenous therapy outside the hospital, increasing NHS center utilization and patient flow, which further facilitates their adoption in the country.
   

The Asia Pacific vascular access devices market is expected to grow at the fastest CAGR of 7.7% over the forecast period.
 

• India, China, Indonesia, and Vietnam are notably upgrading investments in both private and public healthcare facilities. It involves the development of new hospitals, increasing critical care services, and improving surgical and diagnostic capacities, elements that are fuelling higher utilization of vascular access devices in both urban and rural health centers.
   
• Asia-Pacific is also witnessing an epidemic of non-communicable diseases like diabetes, cancer, and renal failure due to urbanization, ageing population, and lifestyle.
   
• They are treated with long-term therapy, dialysis, and repeated blood withdrawal, all of which mean a vast need for vascular access devices like central venous catheters, PICCs, and ports.
   

Japan vascular access devices market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan boasts one of the oldest populations in the world. For example, by the World Economic Forum, over 1 in 10 individuals in the nation are aged 80 or more, and a third of its population is 65 years old and above.
   
• Vascular access devices are crucial for treating patients with cancer, renal disease, and infection among the elderly, and with usage expanding on a larger scale in hospitals, nursing homes, and home care environments, the trend suggests steady growth in vascular access device use among Japanese healthcare facilities.
   
• Japan has the largest proportion of dialysis patients per capita worldwide, mainly for being an aged population and being diabetic. Central vascular access devices, such as tunnelled catheters, are used where arteriovenous fistulas are not feasible. Sustained demand for dialysis therapy propels vascular access device utilization in hospital and outpatient dialysis facilities across Japan.
   

Brazil vascular access devices market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The Brazilian public healthcare system (SUS), an organization associated to the national government, covers free healthcare services for more than 75% of citizens. Due to governmental investment in updating hospitals and improved access to new therapies, the demand for medical devices, such as vascular access devices, is increasing.
   
• As per the Organization for Economic Cooperation and Development (OECD), cancer is among the third leading cause of mortality in Brazil. Additionally, Brazil is also seeing rapid growth in chronic diseases like diabetes and end-stage renal disease.
   
• These diseases are primarily treated with chemotherapy, dialysis, and parenteral nutrition, all dependent on vascular access devices like central lines, ports, and PICCs. This epidemiologic transition is a leading driver of steady market demand.
   

Middle East and Africa: The Saudi Arabia vascular access devices market is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia is experiencing growing healthcare needs because of the widespread lifestyle-related illnesses, such as diabetes, cardiovascular disease, and cancer. The International Diabetes Federation (IDF) reports that Saudi Arabia has one of the highest rates of diabetes prevalence in the world, with about 17.7% of the adult population suffering from it in 2021. These chronic diseases need extensive intravenous therapy, including insulin infusions, chemotherapy, and antibiotic therapy, which necessitate the use of vascular access devices.
   
• The increased emphasis by the government on the management of non-communicable diseases through timely diagnosis and increased options of treatment is further sustaining the demand for vascular access devices in healthcare facilities, especially in the management of these common diseases.
   
• A part of Saudi Vision 2030 initiative involves a considerable healthcare infrastructure investment aimed at increasing hospital capacity in the country, enhancing clinical services, and increasing health technology access. This includes the installation of higher quality vascular access devices with increased safety features to meet international standards of healthcare. The continuous upgrading of hospitals and specialist clinics via public-private partnership (PPP) is fueling the use of vascular access products across the country.
   

Vascular Access Devices Market Share

The market has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced devices for the growing patient population. Companies such as Becton Dickinson and Company, Teleflex, B. Braun, Medtronic, and Fresenius Medical Care are some of the dominant competitors in the market accounting for a combined market share of approximately 60%.
 

Competition in this area arises from continuous technological developments and the ability to offer customized solutions. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer vascular access devices that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Vascular Access Devices Market Companies

Some of the eminent market participants operating in the vascular access devices industry include:

• Access Vascular
• AngioDynamics
• B Braun
• Becton Dickinson and Company
• ConvaTec
• Cook Medical
• Fresenius Medical Care
• ICU Medical
• Medical Components
• Medtronic
• Nipro
• Penumbra
• Teleflex
• Terumo
• Vygon
   
• Becton Dickinson and Company has market leadership in vascular access devices via its safety-engineered catheters, such as the BD Nexiva Closed IV Catheter System. The system minimizes needlestick injuries and bloodstream infections via integrated closed design. PICC and midline catheters by the company feature PowerGlide technology for insertion effectiveness.
   
• Teleflex, through its Arrow product line, pioneers the market. The product is an ultrasound-compatible peripherally inserted central catheters (PICCs) and central venous catheters (CVCs) that ensure more accurate placement. The Arrow VPS Rhythm system applies ECG tip confirmation technology to reduce placement error.
   
• B. Braun specializes in dialysis solution and critical care under its Introcan Safety and Certofix brands with a focus on material compatibility and accuracy engineering. Its Vasofix Safety IV catheter brand includes passive safety devices that reduce needlestick injury risk, and Ecoflon coating reduces thrombogenic complications in long-term use applications.
   

Vascular Access Devices Industry News:

• In January 2025, Penumbra launched the Element vascular access system, a laser-cut hypotube sheath, for the treatment of venous thromboembolism (VTE). Element was designed to be used with the Lightning Flash 2.0 mechanical thrombectomy system for efficient clearance of venous thrombus and treatment of pulmonary embolism. The launch further established Penumbra's leadership in the vascular intervention segment by adding more integrated devices to its portfolio.
   
• In October 2024, Becton, Dickinson and Company (BD), a global medical technology leader, introduced the BD Intraosseous Vascular Access System to enable rapid access for fluid or medication delivery in life-threatening emergency conditions. The introduction complemented BD's emergency care product portfolio and its dedication to enhancing outcomes in high-acuity clinical environments.
   
• In September 2024, Access Vascular, a key company in vascular access innovation through its hydrophilic biomaterial technology, announced a strategic partnership with Capstone Health Alliance, a regional group purchasing organization. The deal made the MIMIX hydrophilic catheters of Access Vascular available to a greater number of facilities through Capstone's more than 300 U.S. hospitals, freestanding health systems, and physician practices.
   
• In November 2023, Becton, Dickinson and Company (BD), global medical technology pioneer, introduced an ultrasound system that allows clinicians to quickly and easily image the vascular space to improve the placement of peripherally inserted central catheters (PICCs), central venous catheters, IV lines, and other vascular access devices. The release boosted BD's vascular access business and furthered its vision to bring procedural excellence and improved patient outcomes to everyday clinical practice.
   

The vascular access devices market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product

• Peripheral vascular access devices
• Central vascular access devices

By Application

• Drug administration
• Fluid and nutrition administration
• Blood transfusion
• Diagnostic testing
• Other applications

By End Use

• Hospitals and clinics
• Ambulatory surgical centers
• Homecare settings
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE